21 results
Nontuberculous mycobacteria (NTM) pulmonary disease treatment (pulmonary MAC)

By Dr. Sara Dong @swinndong via Febrile [febrilepodcast.com
Nontuberculous mycobacteria ... (NTM) pulmonary ... disease treatment ... #Infections #NTM ... #treatment #pulmonaryMAC
Nontuberculous Mycobacteria (NTM) Infections 

Mycobacterial species other than those belonging to the Mycobacterium tuberculosis complex and
Nontuberculous Mycobacteria ... Mycobacterial ... belonging to the Mycobacterium ... Hematologic malignancy ... Nontuberculous #Mycobacteria
Topical drug formulations, comparison and considerations

#pharmacology #table #medications #comparison #drugs #treatment #pharmacotherapy #dermatology
#pharmacology #table ... comparison #drugs #treatment ... pharmacotherapy #dermatology
Tuberculosis Overview

10 million new M. tuberculosis infections/year
Facultative intracellular rod-shaped bacteria
Multidrug-resistant tuberculosis (MDR-TB) accounts for 4.6% of
Species: • Mycobacterium ... infection (NTM) ... Tuberculosis Treatment ... Initiating Treatment ... Diagnosis #Management #Treatment
Here is a quick guide on the common direct-acting antivirals (DAAs) for chronic hepatitis C virus
DAAs #Antivirals #table ... #treatment #hcv ... infectiousdisease #hepatology
Tuberculosis Overview

10 million new M. tuberculosis infections/year
Facultative intracellular rod-shaped bacteria
Multidrug-resistant tuberculosis (MDR-TB) accounts for 4.6% of
Species: • Mycobacterium ... infection (NTM) ... Tuberculosis Treatment ... Initiating Treatment ... Diagnosis #Management #Treatment
Thrombotic Microangiopathy - TTP VS HUS

Big picture points : Often hard to differentiate the two entities,
distinction has HUGE treatment ... and first-line treatment ... Comparison #Diagnosis #Table ... #Hematology
Managing warfarin INR

Warfarin dosage must be individualized according to the patient's response to the drug, and
#pharmacology #treatment ... #medications #table ... decisionaid #cardiology #hematology
Hemophagocytic Lymphohistiocytosis (HLH)
Pathophysiology: Triggering factor (infection,...)→Activation of CD8 T cells (IFN-y) → Excessive activation of macrophages
.), Bacteria (Mycobacteria ... Unknown cause Treatment ... diagnosis #management #treatment ... #summary #rheumatology
TRALI vs TACO - Transfusion Reactions
TRALI:
 • Epidemiology: 0.1% of transfused patientsl
 • Risk factors: Critical
: 33% • Treatment ... : No • Treatment ... Transfusion #Reactions #hematology ... diagnosis #comparison #table